Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier
Biomimetics,
Journal Year:
2025,
Volume and Issue:
10(1), P. 25 - 25
Published: Jan. 3, 2025
Meningitis
is
the
acute
or
chronic
inflammation
of
protective
membranes,
surrounding
brain
and
spinal
cord,
this
inflammatory
process
spreads
throughout
subarachnoid
space.
The
traditional
drug
delivery
methods
pose
a
disadvantage
in
limiting
capacity
crossing
blood–brain
barrier
(BBB)
to
reach
central
nervous
system
(CNS).
Hence,
it
imperative
develop
novel
approaches
that
can
overcome
these
constraints
offer
efficient
therapy
for
meningitis.
Nanoparticle
(NP)-based
therapeutic
have
potential
address
limitations
such
as
penetrating
BBB
achieving
targeted
release
specific
cells
tissues.
This
review
highlights
recent
advancements
nanotechnology-based
approaches,
functionalized
polymeric
nanoparticles,
solid
lipid
nanoparticles
(SLNs),
nanostructured
carriers,
nanoemulsions,
liposomes,
transferosomes,
metallic
NPs
treatment
Recently,
bionics
has
emerged
next-generation
technology
development
ideas
from
biological
principles,
structures,
interactions
neurological
neuroinfectious
diseases.
Despite
their
potential,
more
studies
are
needed
ensure
safety
efficacy
NP-based
systems
focusing
on
critical
aspects
toxicity,
immunogenicity,
pharmacokinetics.
Therefore,
addresses
current
strategies
innovative
nanoparticle
discusses
future
directions
meningitis
therapies.
Language: Английский
Immunity and Coagulation in COVID-19
П. П. Авдонин,
No information about this author
Maria S. Blinova,
No information about this author
Anastasia A. Serkova
No information about this author
et al.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(20), P. 11267 - 11267
Published: Oct. 19, 2024
Discovered
in
late
2019,
the
SARS-CoV-2
coronavirus
has
caused
largest
pandemic
of
21st
century,
claiming
more
than
seven
million
lives.
In
most
cases,
COVID-19
disease
by
virus
is
relatively
mild
and
affects
only
upper
respiratory
tract;
it
often
manifests
itself
with
fever,
chills,
cough,
sore
throat,
but
also
less-common
symptoms.
patients
do
not
require
hospitalization,
fully
recover.
However,
some
infection
leads
to
development
a
severe
form
COVID-19,
which
characterized
life-threatening
complications
affecting
lungs,
other
organs
systems.
particular,
various
forms
thrombotic
are
common
among
COVID-19.
The
mechanisms
for
remain
unclear.
Accumulated
data
indicate
that
pathogenesis
based
on
disruptions
functioning
innate
immune
key
role
primary
response
viral
assigned
two
These
pattern
recognition
receptors,
primarily
members
toll-like
receptor
(TLR)
family,
complement
system.
Both
systems
first
engage
fight
against
launch
whole
range
aimed
at
its
rapid
elimination.
Normally,
their
joint
activity
destruction
pathogen
recovery.
these
can
cause
an
excessive
inflammatory
dangerous
body.
turn,
inflammation
entails
activation
damage
vascular
endothelium,
as
well
hypercoagulable
state
observed
seriously
ill
Activation
endothelium
hypercoagulation
lead
thrombosis
and,
result,
tissues.
Immune-mediated
termed
"immunothrombosis".
this
review,
we
discuss
detail
features
immunothrombosis
associated
potential
underlying
mechanisms.
Language: Английский
Síndrome Hemolítica Urêmica Atípica (SHUA): avanços no diagnóstico e manejo clínico
Giovanna Almeida Vital,
No information about this author
Ana Luíza Carvalho Albuquerque,
No information about this author
Arthur Ramos Rezende
No information about this author
et al.
Europub Journal of Health Research,
Journal Year:
2024,
Volume and Issue:
5(2), P. e5290 - e5290
Published: Aug. 23, 2024
A
Síndrome
Hemolítica
Urêmica
Atípica
(SHUa)
é
uma
condição
rara
e
grave
caracterizada
por
hemólise,
trombocitopenia
insuficiência
renal,
frequentemente
associada
a
disfunções
do
sistema
complemento
alterações
genéticas.
Esta
síndrome
pode
levar
complicações
longo
prazo,
como
hipertensão
doenças
renais
crônicas,
impactando
significativamente
qualidade
de
vida
dos
pacientes.
O
diagnóstico
da
SHUa
tem
avançado
com
introdução
biomarcadores
técnicas
genéticas
que
permitem
identificação
mais
precoce
precisa.
compreensão
aspectos
genéticos
utilização
novas
ferramentas
diagnósticas
têm
possibilitado
abordagem
personalizada
no
tratamento,
embora
os
desafios
persistem,
adaptação
das
terapias
o
manejo
associadas.
tratamento
inclui
uso
inibidores
complemento,
eculizumab,
mostrado
eficácia
em
controlar
atividade
patológica
melhorar
resultados
clínicos.
gestão
doença
exige
um
acompanhamento
contínuo
para
detectar
tratar
complicações,
ajustando
as
conforme
necessário.
monitoramento
regular
essencial
prevenir
progressão
condições
graves
manter
saúde
geral
Além
aspecto
médico,
suporte
psicológico
social
crucial.
impactar
negativamente
bem-estar
emocional
pacientes
suas
famílias,
tornando
importante
oferta
recursos
sociais
adequados
ajudar
na
à
nova
realidade.
deve
ser
multidisciplinar,
integrando
avanços
diagnósticos
terapêuticos
necessidades
emocionais
sociais,
visando
prazo
Membrane-Dependent Reactions of Blood Coagulation: Classical View and State-of-the-Art Concepts
Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology,
Journal Year:
2024,
Volume and Issue:
18(3), P. 200 - 218
Published: Sept. 1, 2024
Language: Английский
Exploring the Intersection of Atypical Hemolytic Uremic Syndrome and Substance Use: A Comprehensive Narrative Review
Abrisham Akbariansaravi,
No information about this author
Anushka Dekhne,
No information about this author
Archi Dhamelia
No information about this author
et al.
Cureus,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 7, 2024
Hemolytic
uremic
syndrome
(HUS)
is
a
thrombotic
microangiopathy
characterized
by
hemolytic
anemia,
renal
failure,
and
thrombocytopenia.
While
the
typical
form
of
HUS
often
associated
with
Shiga
toxin-producing
Escherichia
coli
(STEC)
infections,
atypical
(aHUS)
caused
uncontrolled
complement
system
activation,
leading
to
endothelial
damage,
microthrombi
formation,
other
complications.
Although
aHUS
commonly
linked
genetic
mutations
emerging
evidence
suggests
that
certain
substances,
particularly
illicit
drugs
like
heroin,
cocaine,
ecstasy,
can
also
trigger
this
condition,
adding
complexity
its
diagnosis
management.
This
narrative
review
examines
mechanisms
which
substance
use
lead
aHUS,
discusses
clinical
presentation,
highlights
diagnostic
challenges
in
distinguishing
it
from
microangiopathies,
such
as
thrombocytopenic
purpura
(TTP)
STEC-HUS.
A
thorough
literature
search
identified
relevant
case
reports,
series,
observational
studies,
underscoring
need
for
testing
assays
confirm
users.
The
explores
role
inhibitors,
eculizumab
ravulizumab,
target
underlying
pathophysiology
have
shown
promise
improving
patient
outcomes.
However,
management
substance-induced
remains
challenging
due
limited
data,
varying
presentations,
optimize
treatment
protocols.
Early
recognition
tailored
therapy
are
crucial
effective
Further
research
needed
refine
criteria,
develop
new
therapeutic
approaches,
improve
care
patients
under-recognized
condition.
Language: Английский
Membrane-dependent reactions of blood coagulation: classical view and state-of-the-art concepts
Биологические мембраны Журнал мембранной и клеточной биологии,
Journal Year:
2024,
Volume and Issue:
41(5-6), P. 427 - 447
Published: Nov. 4, 2024
Language: Английский
A potential bimodal interplay between heme and complement factor H 402H in the deregulation of the complement alternative pathway by SARS-CoV-2
Infection Genetics and Evolution,
Journal Year:
2024,
Volume and Issue:
126, P. 105698 - 105698
Published: Dec. 1, 2024
Language: Английский